How One Alzheimer’s Drug Is Changing the U.S. Drug Approval Conversation

<p>After Medicare’s decision to restrict coverage of the controversial new Alzheimer’s drug Aduhelm, we look at how&nbsp;this one drug has forced the nation to reexamine how to balance the needs of desperate patients, incomplete evidence and larger economic realities.</p><br><p>Guests:</p><p><a href="https://www.philgutis.com/" rel="noopener noreferrer" target="_blank">Phil Gutis</a>, Alzheimer’s patient and advocate</p><p><a href="https://medicalethicshealthpolicy.med.upenn.edu/faculty-all/holly-fernandez-lynch" rel="noopener noreferrer" target="_blank">Holly Fernandez Lynch</a>, JD, MBe,&nbsp;John Russell Dickson, MD Presidential Assistant Professor of Medical Ethics, University of Pennsylvania</p><br><p>Have a look at some <a href="https://tradeoffs.org/2022/04/14/aduhelm-aducanumab-medicare-alzheimers/" rel="noopener noreferrer" target="_blank">additional resources and a full transcript</a>.</p><br><p>Support this type of journalism today, <a href="https://tradeoffs.org/donate" rel="noopener noreferrer" target="_blank">with a gift</a>.</p><br><p>Follow us on <a href="https://twitter.com/tradeoffspod" rel="noopener noreferrer" target="_blank">Twitter</a>.&nbsp;</p><br /><hr><p style='color:grey; font-size:0.75em;'> See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for privacy and opt-out information.</p>